Published in Clin Cancer Res on March 24, 2009
Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms. Oncogene (2012) 1.14
In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling. Oncogene (2012) 1.09
Cellular settings mediating Src Substrate switching between focal adhesion kinase tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) tyrosine 734. J Biol Chem (2011) 0.97
Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. Clin Cancer Res (2010) 0.96
Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Mol Cell Biol (2010) 0.94
Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1. Mol Pharm (2010) 0.86
The structural features of Trask that mediate its anti-adhesive functions. PLoS One (2011) 0.85
Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells. Cancer Res (2012) 0.84
Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance. Oncogene (2015) 0.84
Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state. Cell Cycle (2011) 0.84
A tumor-suppressing function in the epithelial adhesion protein Trask. Oncogene (2011) 0.83
Structural requirements for cub domain containing protein 1 (CDCP1) and Src dependent cell transformation. PLoS One (2012) 0.81
CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases. Oncogene (2015) 0.79
CD318/CUB-domain-containing protein 1 expression on cord blood hematopoietic progenitors. Exp Ther Med (2010) 0.76
CUB domain containing protein 1 (CDCP1) modulates adhesion and motility in colon cancer cells. BMC Cancer (2014) 0.76
P2X(7) receptor antagonists display agonist-like effects on cell signaling proteins. Biochim Biophys Acta (2011) 0.75
Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer. Oncotarget (2015) 0.75
CD318 is a ligand for CD6. Proc Natl Acad Sci U S A (2017) 0.75
Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol (1992) 12.96
Cell transformation by pp60c-src mutated in the carboxy-terminal regulatory domain. Cell (1987) 4.63
c-Src and cooperating partners in human cancer. Cancer Cell (2004) 4.22
Cell transformation by the viral src oncogene. Annu Rev Cell Biol (1987) 4.18
Role of Src expression and activation in human cancer. Oncogene (2000) 3.41
The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell (2005) 3.05
Regulation of cell apoptosis by protein kinase c delta. Apoptosis (2003) 2.60
Newest findings on the oldest oncogene; how activated src does it. J Cell Sci (2004) 2.51
v-Src's hold over actin and cell adhesions. Nat Rev Mol Cell Biol (2002) 2.40
Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology (2000) 2.25
Breast cancer risk in women with abnormal cytology in nipple aspirates of breast fluid. J Natl Cancer Inst (2001) 2.13
Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev (1994) 2.05
The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci U S A (2007) 1.79
Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci U S A (1990) 1.76
Src activation regulates anoikis in human colon tumor cell lines. Oncogene (2002) 1.70
Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene (2005) 1.68
Elevated c-yes tyrosine kinase activity in premalignant lesions of the colon. Gastroenterology (1995) 1.66
CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol (2007) 1.64
Identification of subjects at risk for colorectal carcinoma through a test based on K-ras determination in the stool. Gastroenterology (1996) 1.61
Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135 kDa cell surface phosphorylated glycoprotein antigen. Oncogene (2003) 1.59
Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. Mol Carcinog (1998) 1.54
Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proc Natl Acad Sci U S A (2007) 1.52
The road to Src. Oncogene (2004) 1.51
Identification of a novel gene, CDCP1, overexpressed in human colorectal cancer. Oncogene (2001) 1.51
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res (1999) 1.51
Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene (2002) 1.51
Overexpression of pp60c-src elicits invasive behavior in rat colon epithelial cells. Gastroenterology (1998) 1.49
c-Yes tyrosine kinase activity in human colon carcinoma. Oncogene (1993) 1.35
ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Res (2005) 1.35
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res (2004) 1.28
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther (2008) 1.23
Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis. Oncogene (2004) 1.20
Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett (2007) 1.16
Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo. Oncogene (1995) 1.13
Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness. Surgery (2003) 1.11
A transient increase in the activity of Src-family kinases induced by cell detachment delays anoikis of intestinal epithelial cells. Oncogene (2005) 1.07
Protein kinase C delta enhances proliferation and survival of murine mammary cells. Mol Carcinog (2007) 1.04
Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. Biol Chem (2003) 0.98
Elevated c-Src protein expression is an early event in colonic neoplasia. Lab Invest (1998) 0.97
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell (2006) 27.36
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature (2007) 6.56
A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell (2009) 6.03
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol (2008) 5.10
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol (2010) 4.75
Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med (2011) 4.47
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol (2008) 4.42
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell (2012) 3.82
Bypassing a kinase activity with an ATP-competitive drug. Science (2003) 3.71
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol (2010) 3.19
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst (2013) 2.56
Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol (2011) 2.55
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol (2010) 2.42
Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med (2010) 2.42
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res (2003) 2.33
Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer. Cell Stem Cell (2008) 2.24
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol (2010) 2.23
TFIIH-associated Cdk7 kinase functions in phosphorylation of C-terminal domain Ser7 residues, promoter-proximal pausing, and termination by RNA polymerase II. Mol Cell Biol (2009) 2.20
The Saccharomyces cerevisiae Mob2p-Cbk1p kinase complex promotes polarized growth and acts with the mitotic exit network to facilitate daughter cell-specific localization of Ace2p transcription factor. J Cell Biol (2002) 2.04
The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest (2009) 2.01
HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J Clin Invest (2010) 2.00
Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma. J Mol Med (Berl) (2011) 1.87
A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov (2012) 1.87
Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife (2013) 1.85
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res (2003) 1.83
Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. Am J Surg Pathol (2013) 1.83
Chemical-genomic dissection of the CTD code. Nat Struct Mol Biol (2010) 1.76
HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res (2010) 1.73
Chemical genetics reveals a role for Mps1 kinase in kinetochore attachment during mitosis. Curr Biol (2005) 1.70
Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene (2005) 1.68
Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest (2009) 1.67
Mek1 kinase activity functions downstream of RED1 in the regulation of meiotic double strand break repair in budding yeast. Mol Biol Cell (2003) 1.66
The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol (2010) 1.54
Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res (2002) 1.50
Molecular predictors of 3D morphogenesis by breast cancer cell lines in 3D culture. PLoS Comput Biol (2010) 1.46
Picomolar sensitivity MRI and photoacoustic imaging of cobalt nanoparticles. Proc Natl Acad Sci U S A (2009) 1.43
Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat (2010) 1.42
Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages. J Cell Sci (2008) 1.39
PIKfyve regulation of endosome-linked pathways. Traffic (2009) 1.39
Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat (2011) 1.39
Calreticulin interacts with C/EBPalpha and C/EBPbeta mRNAs and represses translation of C/EBP proteins. Mol Cell Biol (2002) 1.38
Non-competitive androgen receptor inhibition in vitro and in vivo. Proc Natl Acad Sci U S A (2009) 1.37
The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med (2007) 1.37
Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett (2008) 1.34
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J Clin Oncol (2011) 1.32
Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat (2007) 1.31
Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res (2011) 1.30
TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res (2011) 1.30
Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl Acad Sci U S A (2006) 1.27
Morphometic analysis of TCGA glioblastoma multiforme. BMC Bioinformatics (2011) 1.26
Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents. Proc Natl Acad Sci U S A (2010) 1.25
A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res (2008) 1.25
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Imaging (2007) 1.21
A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat (2015) 1.12
The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression. Curr Drug Targets (2010) 1.10
Netrin-4 induces lymphangiogenesis in vivo. Blood (2010) 1.10
CcbP, a calcium-binding protein from Anabaena sp. PCC 7120, provides evidence that calcium ions regulate heterocyst differentiation. Proc Natl Acad Sci U S A (2005) 1.09
Experimental models to study lymphatic and blood vascular metastasis. J Surg Oncol (2011) 1.07
Design of drug-resistant alleles of type-III phosphatidylinositol 4-kinases using mutagenesis and molecular modeling. Biochemistry (2008) 1.06
Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer Res (2014) 1.06
Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol (2008) 1.05
Biocompatibility and reduced drug absorption of sol-gel-treated poly(dimethyl siloxane) for microfluidic cell culture applications. Anal Chem (2010) 1.04
The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation. Am J Pathol (2009) 1.04
Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine. Curr Protoc Pharmacol (2013) 1.04
Analysis of 3-phosphoinositide-dependent kinase-1 signaling and function in ES cells. Exp Cell Res (2008) 1.04
Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer. Mol Pharmacol (2007) 1.04
Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes. Clin Cancer Res (2005) 1.03
Netrin-4 activates endothelial integrin {alpha}6{beta}1. Circ Res (2011) 1.02
Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma. J Clin Oncol (2006) 1.02
Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. J Nucl Med (2013) 1.01
A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res (2009) 1.01
Outgrowth of drug-resistant carcinomas expressing markers of tumor aggression after long-term TβRI/II kinase inhibition with LY2109761. Cancer Res (2011) 1.01
A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res (2009) 1.01
Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase. Genes Cancer (2011) 1.01
Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity. Cancer Discov (2013) 1.00
Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res (2004) 1.00
Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat (2012) 0.99
Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Mol Cell Biol (2010) 0.94
HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J (2012) 0.94
Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. Cancer Res (2011) 0.93
Photocatalytic degradation of RhB over TiO2 bilayer films: effect of defects and their location. Langmuir (2010) 0.92
Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release (2009) 0.92
Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imaging (2007) 0.92
Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. Cancer Res (2013) 0.91
Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. Breast Cancer Res Treat (2011) 0.91
Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res (2009) 0.90